NDAORALTABLET
Approved
Apr 1960
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 12h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ROBAXISAL is a fixed-dose oral tablet combining aspirin (analgesic/anti-inflammatory) and methocarbamol (muscle relaxant), approved in 1960. It is indicated for relief of discomfort associated with acute musculoskeletal conditions. The combination works by reducing pain and inflammation while relaxing skeletal muscle tension.
LOE Approaching
As a mature product approaching loss of exclusivity with moderate competitive pressure (30%), the brand team is likely focused on defensive positioning and cost optimization rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on ROBAXISAL offers limited career growth given its approaching LOE and low linked job count; roles are primarily defensive and cost-management focused. This assignment suits professionals seeking stable, established product experience or those transitioning to other brands.
Brand ManagerProduct Manager
Worked on ROBAXISAL at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.